





# Factors influencing adherence to antiretroviral therapy among HIV-infected adults in Cross River State, Nigeria: a cross-sectional study

Anastasia Ikilishi Isika, Adamu Shehu, Tukur Dahiru, lukuk Irank Obi, Afiong Oboko Oku, Muhammad Shakir Balogun, Aniekan Etokidem

**Corresponding author:** Izuchukwu Frank Obi, Nigeria Field Epidemiology and Laboratory Training Program, Abuja, Nigeria. obifrank03@gmail.com

Received: 03 Sep 2022 - Accepted: 07 Nov 2022 - Published: 09 Dec 2022

Keywords: Adherence, antiretroviral therapy, predictors of adherence, highly active antiretroviral therapy, Nigeria

**Copyright:** Anastasia Ikilishi Isika et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Cite this article:** Anastasia Ikilishi Isika et al. Factors influencing adherence to antiretroviral therapy among HIV-infected adults in Cross River State, Nigeria: a cross-sectional study. Pan African Medical Journal. 2022;43(187). 10.11604/pamj.2022.43.187.37172

Available online at: https://www.panafrican-med-journal.com//content/article/43/187/full

## Factors influencing adherence to antiretroviral therapy among HIV-infected adults in Cross River State, Nigeria: a cross-sectional study

Anastasia Ikilishi Isika<sup>1,2,3</sup>, Adamu Shehu<sup>4</sup>, Tukur Dahiru<sup>4</sup>, Izuchukwu Frank Obi<sup>3,5,6,&</sup>, Afiong Oboko Oku<sup>1,2</sup>, Muhammad Shakir Balogun<sup>3</sup>, Aniekan Etokidem<sup>1,2</sup>

<sup>1</sup>Department of Community Medicine, University of Calabar, Calabar, Cross River State, Nigeria,

<sup>2</sup>Department of Community Medicine, University of Calabar Teaching Hospital, Calabar, Cross River State, Nigeria, <sup>3</sup>Nigeria Field Epidemiology and Laboratory Training Program, Abuja, Nigeria, <sup>4</sup>Department of Community Medicine, College of Medicine, Ahmadu Bello University, Zaria, Nigeria, <sup>5</sup>Department of Community Medicine, University of Nigeria Teaching Hospital, Enugu, Nigeria, <sup>6</sup>Center for Translation and Implementation Research, College of Medicine, University of Nigeria, Nsukka, Nigeria



#### Corresponding author

Izuchukwu Frank Obi, Nigeria Field Epidemiology and Laboratory Training Program, Abuja, Nigeria

#### **Abstract**

Introduction: improved access to antiretroviral therapy (ART) has significantly increased the survival and quality of life of HIV-infected persons. Strict adherence to antiretroviral therapy (ART) is crucial if viral suppression must remain optimal. We assessed predictors of adherence to ART among adult patients in Cross River State (CRS), Nigeria. Methods: a cross-sectional survey was conducted among 999 adult patients on ART in selected secondary and tertiary health facilities in CRS from January to June 2017. Respondents were recruited using multistage technique. Data were collected using а pre-tested intervieweradministered questionnaire. Adherence defined as clients taking at least 95% of their pills in the last seven days. Multivariate analysis was performed to determine predictors of adherence at 5% level of significance. **Results:** majority (70.5%) of the respondents were females with a mean age of 43.7 ± 11.1 years. The self-reported adherence rate was 60.1%. The commonest reasons for nonadherence was client travelling out of home, being busy, forgetting and lack of food. The significant predictor identified in this study was being on firstline drugs (OR=3.677, 95% C.I=2.523-5.358), were 3 times more likely to have good adherence. Predictors of poor-adherence were alcohol intake (OR=0.382, 95% C.1=0.262-0.559), medications (OR=0.502, 95% C.I=0.381-0.661), CD4 cell count ≥ 500 (OR=0.723, 95% C.I=0.543-0.964), poor attitude to HIV status and medication (OR=0.713, 95% C.I=0.512-0.994) and family support (OR=0.736,95% C.I=0.544-0.995). Conclusion: adherence to ART among clients in this study was fair. Majority of the reasons for pooradherence were client-related. There is need for targeted counselling to improve adherence.

#### Introduction

With an estimated global prevalence of 0.8%, an estimated 38.4 million people living with HIV (PLHW) and 860,000 AIDS-related mortality globally in 2021, HIV continues to be a major public health problem [1,2]. Sub-Saharan Africa (SSA) accounts for over two-thirds of the global burden of HIV with Nigeria having one of the highest rates of new infection in SSA [3]. In 2020, 1.7 million people in Nigeria were living with HIV, with adult prevalence (15-45 years) of 1.3%, with estimated 86,000 new infections and 49,000 AIDSrelated new deaths [4]. The south-south region of Nigeria, where the study site, Cross-River State is located, has the highest prevalence of HIV in Nigeria (5.5%) [5], while the prevalence in Cross River State is 1.7% [6].

Improved access to highly active antiretroviral therapy (HAART) has significantly improved quality of life, increased survival and reduced the risk of transmission of HIV to infants and sexual partners [7-9]. However, to obtain a successful treatment outcome, adherence to HAART needs to be greater than 95% otherwise; treatment failure that has been linked to increased mortality may result [10-13]. Several studies have measured adherence by expressing the number of doses taken as a percentage of the number of doses prescribed. Others have measured adherence through; patient self-report, pharmacy drug pickup and electronic methods (e.g. Medication Event Monitoring System (MEMS) cap) [13-16]. Some factors that have been reported to be associated with good adherence in Nigeria include providing free medications, family and community support, availability of treatmentsupporter, and family-based care if more than one member is on HAART, others [13,17]. Poor adherence to HAART has been linked to poor patient-caregiver relationship, high pill burden, forgetfulness, AIDS dementia complex, depression, and lack of patient education amongst others [13].



Some strategies that have been deployed overtime to improve adherence include treatment education for patients and partners, treatmentsupporter involvement, peer health education, assessment and reinforcement adherence during follow-up, directly observed therapy and addressing life-style factors [13,17]. A cross-sectional study conducted in a tertiary health facility in the same setting in 2013, reported a low adherence rate of 59.9% with participants citing being busy, forgetting, feeling depressed and traveling out as reasons for skipping their medications. Furthermore, predictors of good adherence were: perceived improved health status, reduced pill load and nonuse of herbal remedies [16]. However, factors influencing adherence are known to be contextspecific and change over time, hence the need to generate robust evidence on the influencing adherence to ART in our environment to guide interventions targeted at improving adherence. The study aimed to identify factors influencing adherence to ART among adult patients accessing care in secondary and tertiary healthcare facilities in urban and rural areas in Cross River State (CRS), Nigeria.

#### **Methods**

Study area and setting: the study was conducted in Cross River State located in the southern part of Nigeria [18], with Calabar as its capital city [19]. The State shares boundaries with Akwa Ibom State to the South-West, Ebonyi and Abia to the West, Benue to the North, the Republic of Cameroon to the East and the Atlantic Ocean to the West. Cross River has 18 LGAs, with an estimated population of 3,674,951 (2015 estimate), projected from the 2006 census population at a growth rate of 2.9% [19]. The State is composed of several ethnic groups, which include the Efik, Ejagham, Yakurr, Bahumono, Bette, Yala, Igede, Ukelle, Utukwang and the Bekwarra [19]. The prevalence of HIV in the State dropped from 6.6% in 2014 to 1.7% in 2018 [20,21]. Cross River State, sandwiched between Benue and Akwa Ibom States, the two States with the highest prevalence of HIV in Nigeria, is a choice tourist destination with a large influx of visitors [6]. The four study facilities provide comprehensive HIV care (paediatric, adult and prevention of maternal to child transmission of HIV services) and run clinics from Monday through Friday. University of Calabar Teaching Hospital, the only tertiary healthcare facility in the State, has 5,800 patients accessing HIV care, of which more than 3,900 were on HAART; while General Hospital Calabar, had 11,057 patients with 3,294 on HAART.

**Study design:** a cross-sectional facility-based descriptive study.

**Study population:** we studied 999 adult (≥18 years) HIV-infected patients receiving treatment in three general hospitals (one from each senatorial district) and the only teaching hospital in the State.

Eligibility criteria: all the adult patients on HAART for at least three months prior to the study were eligible to participate. People living with HIV/AIDS (PLWHA) who were too sick, pregnant, had cognitive impairment or other disabilities like deafness, were excluded from the study.

Sample size determination: using the Leslie Kish formula for determination of minimum sample size based on the assumption of ART adherence rate of 59.9% among adult HIV-infected patients from a similar study [16], 5% precision, design effect of 2.4 and adjusting for a non-response rate of 10% non-response, the desired sample size was determined to be 985 rounded to 999 participants. This sample size was proportionately allocated to the study facilities.

**Sampling technique:** a multi-stage sampling involving three-stage was used to select participants for the study. The first stage involved selection of one local government area (LGA) each from the three senatorial districts in the State through simple random sampling (SRS). In the second stage (selection of study facilities), one



general hospital was selected by SRS from each of the three selected LGA, while the only teaching hospital in the State was also included, giving a total of four selected facilities (General Hospital Calabar, General Hospital Ugep and General Hospital Obanliku representing the south, central and northern senatorial districts respectively, with University of Calabar Teaching Hospital included as the only teaching hospital in the State). Systematic random sampling was used in the third stage to recruit participants from the selected facilities based on proportionate allocation of sample size to each facility.

#### Data collection

**Study instruments:** a pre-tested, semi-structured, interviewer-administered questionnaire adapted from a similar study [16] was used to collect information on participants' socio-demographic characteristics, treatment history (when treatment commenced, type of HAART regimen), adherence profile and attitude to HAART.

#### Data management and analysis

Quantitative survey: collected data uploaded to a secure server were exported in Microsoft Excel XLS format, cleaned in Excel spreadsheet and analysed with SPSS version 23. Frequencies, percentages, mean and standard deviations were used as appropriate in descriptive statistics. Adherence to HAART in the seven days preceding the interview was measured by self-report. The questions were adapted from brief medication questionnaire self-report tool for screening adherence and barriers to adherence [16]. The degree of adherence from patient self-report was estimated using the following formula [22].

% adherence over last 7 days =  $\frac{\# Doses \ should \ have \ taken - \# Missed \ doses}{\# Doses \ should \ have \ taken} \times 100\%$ 

For the purpose of the study, adherence score of 95% and above represented good adherence while scores of less than 95% were rated as poor adherence. At bivariate analysis, association between HAART adherence and independent variables such as socio-demographic and

treatment characteristics were determined using Chi-square tests with corresponding p-values. Variables that had a p-value of ≤ 0.2 at bivariate analysis were entered into the logistic regression model to determine the predictors of HAART adherence. The results of the logistic regression were reported using odds ratios and 95% confidence intervals. All statistical analyses were performed at 5% level of significance.

Ethical considerations: ethical approval for this study was obtained from the Health Research Ethics Committees of University of Calabar Teaching Hospital (reference: UCTH/HREC/33/519) and the State Ministry of Health (reference: RP/REC/2016/422). Written informed consents were obtained from the participants after the details of the study and its voluntariness was explained to them. Safety and confidentiality of collected data was ensured throughout the study.

#### **Results**

The mean age of the 999 study participants was 43.7 ± 11.1 years. Majority 704 (74.5%) were females, married 466 (46.6%), attended secondary education 436 (43.6%), were self-employed 482 (48.2%), and earned less than ₩ 20,000 (USD 50) monthly 565 (56.5%) (Table 1). In addition, majority 842 (84.2%) of respondents were on first line drugs while 515 (51.6%) were on once daily regimen. Adherence pattern revealed that a little over half, 541 (54.1%) of the respondents did not miss any tablet in the last week, while 439 (43.9%) missed 1- 2 tablets. Majority of the respondents 743 (74.4%) refill their drugs every 2 months, while 160 (16.0%) refills monthly. Additionally, 591 (59.2%) of the respondents spent ≤ ₩ 500 (USD 1.1) on transportation to the health facility (Table 2).

Out of 999 participants, 60.1% had good adherence, defined as taking at least 95% of their pills during the previous 7 days prior to the study. The most common reasons given by respondents for not adhering to HAART were mostly client related. They include being busy (39.9%), forgot



(14.0%), no food (11.7%), fear of known (9.9%), felt unwell (8.5%). The least common reasons for not adhering to HAART were mostly provider related. These include dissatisfaction with treatment (0.6%), long clinic waiting time (0.8%), unfriendly health workers (0.8%), and pill having smell (0.8%) (Figure 1).

Bivariate analysis revealed that respondents who resided in urban settlements ( $\chi^2$ = 4.314, p=0.038), had formal education ( $\chi^2$ = 5.825, p=0.016), did not take any form of alcohol ( $\chi^2$ = 21.282, p=<0.001), did not receive any form of family support  $(\chi^2 = 5.019, p=0.025)$ , those on first line ART  $(\chi^2 = 46.199, p = < 0.001)$ , once daily regimen  $(\chi^2 = 27.148, p = < 0.001)$ , regimen had no food restrictions (Fisher's Exact Test = 0.000, p=0.025), did not experience side-effects ( $\chi^2$ = 4.535, p=0.033), and whose CD4 cell count were ≥ 500 ( $\chi^2$ = 9.591, p=0.002) were more likely to have good adherence to **HAART** compared their counterparts (Table 3).

On multivariate analysis, respondents who were on first line drugs (OR= 3.68, 95% C.I = 2.52 -5.36), were 3 times more likely to have good adherence. However, respondents who drank any form of alcohol (OR=0.38, 95% C.I=0.26-0.56), were on twice-daily medication (OR=0.50, 95% C.I=0.38-0.66), those who had CD4 cell count ≥ 500 (OR=0.72, 95% C.I=0.54-0.96), had poor attitude towards their HIV-status and medication (OR=0.71, 95% C.I=0.51-0.99) as well as those who had any family support (OR=0.736, 95% C.I=0.54-0.99) were less likely to have good adherence (Table 4).

#### **Discussion**

This study assessed factors influencing adherence to HAART among adults infected with HIV in Cross River State, Nigeria. Only three-fifth of the respondents had good adherence. This adherence level is suboptimal considering the fact that the respondents were patients who came for refill. This suggests that adherence could even be worse among those who could not keep clinic

appointment. This reported low adherence level is just a slight improvement over 59.9% adherence level reported by a previous study in the State [16]. Furthermore, other studies conducted in public and private facilities in Nigeria have reported adherence rates ranging from of 58% - 95.3% [14,17,20,21,23,24] in public facilities. The disparity of adherence rates across studies may be due to different geographical locations and may be due to variations in how adherence was measured. Our study-assessed adherence using self-report and timing while some of the other studies used pill count. Sub-optimal adherence to HAART as found in our study calls for urgent interventions targeted at improving adherence.

The most common reasons given for pooradherence were client related. About two-fifth of the respondents cited being busy as one of the major reasons for not adhering to medications. This finding is consistent with the findings from other studies. Studies conducted in Ethiopia revealed that the reasons given for missing drugs were being away from home and being busy with other things and that those whose medicationtaking time interfered with their daily routines had more than fifteen times higher odds of nonadherence compared to those whose medication schedules did not interfere with their daily activities [25-27]. Therefore, reducing the pill burden and frequency of taking the drugs could improve adherence. The implication of this is that drug manufacturers should formulate drugs where a single tablet should contain all the major ingredients and the dosage frequency reduced to once daily medication in order to optimize adherence. Other reasons for poor-adherence include forgot, not having food, fear of being known, felt unwell, no need, too many drugs, fear of side effects, dosing, amongst others. These reasons have been reported by other studies as contributing to non-adherence [15,16,27-29]. Only few respondents mentioned provider related factors like long waiting time, dissatisfaction with treatment, unfriendly health worker attitude and unavailable drugs as reasons for non-adherence. Health system and provider-related factors not



being cited much as reasons for non-adherence to HAART in this study suggests high quality service delivery at the study facilities.

This study also revealed that respondents who took alcohol in any form were less likely to have good adherence to their medication. This is in keeping with a study in Enugu, Nigeria which revealed that respondents who did not take alcohol had approximately four times the odds of being adherent to their medications when compared to those who took alcohol [15]. Other studies have reported similar findings in other parts of Nigeria [15,29] and Ethiopia [30]. The use of alcohol and other addictive substances have been linked with poor adherence to HAART. This could be due to the tendency of these substances to cause forgetfulness, poor organization and diversion of monetary resources [17,24,30-32]. It is therefore important that patients on HAART be counselled to avoid alcohol intake and use of other addictive substances that may cause memory impairment.

Furthermore, respondents who were on twicedaily HAART regimen were less likely to have good adherence. Similar findings have been reported by studies in other parts of Nigeria [17], Peru [33] and the United States of America [31]. This is understandable because people tend to be busy and may find it difficult to incorporate their drug schedule into their daily activities. Therefore, reducing HAART dosing frequency and pill burden should always be the target. Closely linked to pillburden is the finding that respondents on first-line drugs were three times more likely to have good adherence compared to those on second-line drugs. This has also been reported by studies from other parts of Nigeria [24]. The study also found that respondents whose CD4 cell counts were above 500 cells/mm<sup>3</sup> were less likely to have good adherence. This may be attributed to the reduced likelihood of illness in such patients; hence, the feeling of being healthy may make them not see the need for the drugs. This might lead to relapse and drug failure. It is therefore important to always educate the patients on the need to continue adhering to their medications in order to sustain the gains achieved. Surprisingly, in contrast with reports from other studies [34], this study found that respondents who had no family support had better adherence compared to those with family support. The reason behind this finding is unclear and calls for further investigation.

This study has provided insight on some important context-specific factors influencing adherence to HAART in a resource-limited setting. However, the study has a few limitations. This study being a cross-sectional study which relied on respondents' ability to accurately recall how they took their HAART, may have been prone to recall bias. To make it easier for clients to accurately remember their experience, we limited recall to the past seven days. Furthermore, clients' self-report of adherence may have been prone to social desirability bias whereby respondents report good adherence in order to please the investigators. We reassured participants that their response would in no way affect their treatment in the facility. We also ensured they had privacy during questionnaire administration with no health facility worker around. The findings from this study are generalizable to similar populations especially in low resource settings.

#### Conclusion

This study showed a suboptimal adherence level among clients accessing care in facilities in Cross River State, Nigeria. The main predictors of good adherence include not drinking any form of alcohol, being on once-daily medication, being on first-line drugs, having no family support, as well as having a CD4 count above 500 cell/mm<sup>3</sup>. The authors therefore recommend tailored adherence enhancing strategies targeted at identified barriers of good adherence.

#### What is known about this topic

 Adherence to ART among HIV-infected patients is essential for optimal clinical outcomes;



 Adherence to ART varies in different settings and factors influencing adherence also vary in different settings.

#### What this study adds

- Adherence to ART among adults infected with HIV is low in Cross River State, Nigeria;
- The major reasons for non-adherence were client related and include feeling depressed, travelling out of home, being busy and forgetting;
- Predictors of good adherence to ART include not drinking any form of alcohol, being on once-daily medication, being on first-line drugs, having no family support, as well as having a CD4 count ≥500.

#### **Competing interests**

The authors declare no competing interests.

#### **Authors' contributions**

Anastasia Ikilishi Isika conceived, designed and implemented the study; Adamu Shehu, Tukur Dahiru, Afiong Oboko Oku and Aniekan Etokidem made intellectual input to study design and implementation; Izuchukwu Frank Obi and Muhammad Shakir Balogun contributed to data collection and analysis; Anastasia Ikilishi Isika and Izuchukwu Frank Obi wrote the first draft of the manuscript. All authors reviewed, edited, read and approved the final version of this manuscript.

#### **Acknowledgments**

The authors acknowledge the support and assistance by the members of management and staff of the ART Clinic, Department of Family Medicine, University of Calabar Teaching Hospital, General Hospitals Calabar, Ugep and Obanliku. Would also acknowledge the contribution of the research assistants to the success of this work and the research team at the Demographic Health Surveillance System; University of Calabar especially Dr Arikpo Iwara and Mr. Anthony Okoro

who helped to develop the electronic tool used that made the job quite easy.

#### **Tables and figure**

**Table 1**: socio-demographic characteristics of respondents on HAART, Cross River State, 2017

**Table 2**: clinical characteristics of respondents on HAART, Cross River State, 2017

**Table 3**: association between respondents' sociodemographics and adherence to HAART

**Table 4**: association between treatment profile and adherence to HAART among respondents

**Figure 1**: respondents' reasons for missing HAART, Cross River State Nigeria, 2017

#### References

- 1. World Health Organization. HIV: Key facts. 2022. Accessed September 7, 2022.
- 2. Global HIV & AIDS statistics Fact sheet. The Joint United Nations Programme on HIV and AIDS (UNAIDS). Accessed December 1, 2022.
- 3. The Joint United Nations Programme on HIV and AIDS (UNAIDS). DOCUMENTS: UNAIDS data 2021. 2021. Accessed September 7, 2022.
- 4. Avert. At a glance: HIV in Nigeria: The largest HIV epidemic in West and Central Africa. Be in The Know; 2022 [updated 17<sup>th</sup> March, 2022]. Accessed September 7, 2022.
- National Agency for the Control of AIDS. REVISED NATIONAL HIV AND AIDS STRATEGIC FRAMEWORK 2019-2021. 2019. Accessed May 11, 2021.
- States With The Highest HIV Rate In Nigeria 2020/2021. Public Health Nigeria. 2020. Accessed May 11, 2021.
- 7. Ataro Z, Motbaynor B, Weldegebreal F, Sisay M, Tesfa T, Mitiku H et al. Magnitude and causes of first-line antiretroviral therapy regimen changes among HIV patients in Ethiopia: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2019 Nov 1;20(1): 63. PubMed | Google Scholar



- 8. Eggleton JS, Nagalli S. Highly Active Antiretroviral Therapy (HAART). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. 2020. PubMed| Google Scholar
- 9. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. World Health Organization. 2016. PubMed | Google Scholar
- 10. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015. Accessed February 19, 2017.
- 11. Alvi Y, Khalique N, Ahmad A, Khan HS, Faizi N. World Health Organization Dimensions of Adherence to Antiretroviral Therapy: A Study at Antiretroviral Therapy Centre, Aligarh. Indian J Community Med. 2019 Apr-Jun;44(2): 118-124. PubMed | Google Scholar
- 12. World Health Organization. National Guidelines for HIV and AIDS Treatment and Care in Adolescents and Adults. Abuja: Federal Ministry of Health; 2007. Accessed February 16, 2017.
- 13. Anyaike C, Atoyebi OA, Musa OI, Bolarinwa OA, Durowade KA, Ogundiran A *et al*. Adherence to combined Antiretroviral therapy (cART) among people living with HIV/AIDS in a Tertiary Hospital in Ilorin, Nigeria. Pan African Medical Journal. 2019;32: 10. **PubMed Google Scholar**
- 14. Chime OH, Ndibuagu EO, Orji CJ. Rates and predictors of adherence and retention for antiretroviral therapy among HIV-positive adults in Enugu, Nigeria. Malawi Med J. 2019 Sep 1;31(3): 202-211. PubMed | Google Scholar
- 15. Oku AO, Owoaje ET, Ige OK, Oyo-Ita A. Prevalence and determinants of adherence to HAART amongst PLHIV in a tertiary health facility in south-south Nigeria. BMC Infect Dis. 2013 Aug 30;13: 401. PubMed| Google Scholar

- 16. Chijioke-Nwauche IN, Akani Y. Influencing Factors of Adherence to Antiretroviral Drugs among People Living with HIV in South-South Nigeria. Saudi J Med Pharm Sci. 2021;7(2): 145-52. Google Scholar
- 17. Brief History of Cross-River State. Nigeria Galleria. Accessed December 1, 2022.
- 18. Cross River State, Nigeria. Sister States Maryland. Accessed December 1, 2022.
- 19. Nigeria Population growth rate. Index Mundi; 2021. Accessed December 1, 2022.
- 20. PRESS RELEASE: New survey results indicate that Nigeria has an HIV prevalence of 1.4%. UNAIDS; 2021. Accessed July 13, 2021.
- 21. Nigeria Population Commission. Nigeria demographic and health survey 2018. NPC, ICF. 2019. **Google Scholar**
- 22. Gaifer Z, Boulassel MR. Comparative Analysis of two Methods of Measuring Antiretroviral Therapy Adherence in HIV-Infected Omani Patients. J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18: 2325958219867316. PubMed Google Scholar
- 23. Kasumu L, Balogun M. Knowledge and attitude towards antiretroviral therapy and adherence pattern of HIV patients in southwest Nigeria. Int J Infect Control. 2014 Jul 12;10(3). **Google Scholar**
- 24. Umeokonkwo CD, Onoka CA, Agu PA, Ossai EN, Balogun MS, Ogbonnaya LU. Retention in care and adherence to HIV and AIDS treatment in Anambra State Nigeria. BMC Infect Dis. 2019 Jul 22;19(1): 654. PubMed | Google Scholar
- 25. Dibaba B, Hussein M. Predictors of Adherence to Highly Active Antiretroviral Therapy among Low Income Adult Patient in Arsi Zone. ARC J AIDS. 2016;1(1): 3-6. **Google Scholar**
- 26. Aychiluhm SB, Tadesse AW, Urmale Mare K, Melaku MS, Ibrahim IM, Ahmed O et al. Level of non-adherence and its associated factors among adults on first-line antiretroviral therapy in Amhara Regional State, Ethiopia. PLoS One. 2021 Aug 9;16(8): e0255912. PubMed | Google Scholar



- 27. Tegegne AS, Ndlovu P, Zewotir T. Factors affecting first month adherence due to antiretroviral therapy among HIV-positive adults at Felege Hiwot Teaching and Specialized Hospital, north-western Ethiopia; a prospective study. BMC Infect Dis. 2018 Feb 20;18(1): 83. PubMed | Google Scholar
- 28. Zahedi-Spung L, Young M, Haddad LB, Badell ML. Perceived Barriers to Antepartum HIV Medication Adherence in HIV Infected Pregnant Women. Infect Dis Obstet Gynecol. 2018 Oct 16;2018: 4049212. PubMed | Google Scholar
- 29. Nduaguba SO, Soremekun RO, Olugbake OA, Barner JC. The relationship between patient-related factors and medication adherence among Nigerian patients taking highly active anti-retroviral therapy. Afr Health Sci. 2017;17(3): 738-45. PubMed | Google Scholar
- 30. Chaka TE, Abeya SG, Adlo AM, Abebe TW, Hamuse SD, Lencha MT et al. Antiretroviral Therapy: Level of Adherence and Its Determinants Among Patients on Treatment in Different Health Facilities. A Cross Sectional Study in Oromia Regional State, Ethiopia. J AIDS Clin Res. 2016 Oct 25;7(11): 1-7. Google Scholar

- 31. Buscher A, Hartman C, Kallen MA, Giordano TP. Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naïve HIV patients. Int J STD AIDS. 2012 May;23(5): 351-5. PubMed Google Scholar
- 32. Schensul SL, Ha T, Schensul JJ, Vaz M, Singh R, Burleson JA *et al.* The Role of Alcohol on Antiretroviral Therapy Adherence Among Persons Living With HIV in Urban India. J Stud Alcohol Drugs. 2017 Sep;78(5): 716-724. PubMed | Google Scholar
- 33. Leyva-Moral JM, Loayza-Enriquez BK, Palmieri PA, Guevara-Vasquez GM, Elias-Bravo UE, Edwards JE *et al*. Adherence to antiretroviral therapy and the associated factors among people living with HIV/AIDS in Northern Peru: a cross-sectional study. AIDS Res Ther. 2019 Aug 28;16(1): 22. **PubMed Google Scholar**
- 34. Obirikorang C, Selleh PK, Abledu JK, Fofie CO. Predictors of Adherence to Antiretroviral Therapy among HIV/AIDS Patients in the Upper West Region of Ghana. ISRN AIDS. 2013 Dec 10;2013: 1-7. PubMed | Google Scholar





| Table 1: socio-demographic cha | able 1: socio-demographic characteristics of respondents on HAART, Cross River State, 2017 |                   |  |  |  |
|--------------------------------|--------------------------------------------------------------------------------------------|-------------------|--|--|--|
| Variables                      | Frequency (N =999)                                                                         | Percentage (100%) |  |  |  |
| Age distribution (years)       |                                                                                            |                   |  |  |  |
| ≤ 29                           | 98                                                                                         | 9.9               |  |  |  |
| 30 - 39                        | 268                                                                                        | 26.8              |  |  |  |
| 40 - 49                        | 307                                                                                        | 30.7              |  |  |  |
| ≥ 50                           | 326                                                                                        | 32.6              |  |  |  |
| Median age (years) ± SD        | 43.7 ± 11.1 years                                                                          |                   |  |  |  |
| Sex                            |                                                                                            |                   |  |  |  |
| Male                           | 295                                                                                        | 29.5              |  |  |  |
| Female                         | 704                                                                                        | 70.5              |  |  |  |
| Religion                       |                                                                                            |                   |  |  |  |
| Christianity                   | 990                                                                                        | 99.1              |  |  |  |
| Islam                          | 8                                                                                          | 0.8               |  |  |  |
| Traditional                    | 1                                                                                          | 0.1               |  |  |  |
| Marital status                 |                                                                                            |                   |  |  |  |
| Single                         | 224                                                                                        | 22.4              |  |  |  |
| Married / cohabiting           | 466                                                                                        | 46.6              |  |  |  |
| Divorced / Separated           | 70                                                                                         | 7.1               |  |  |  |
| Widowed                        | 239                                                                                        | 23.9              |  |  |  |
| Highest level of education     |                                                                                            |                   |  |  |  |
| None                           | 93                                                                                         | 9.3               |  |  |  |
| Primary                        | 236                                                                                        | 23.6              |  |  |  |
| Secondary                      | 436                                                                                        | 43.6              |  |  |  |
| Tertiary                       | 234                                                                                        | 23.5              |  |  |  |
| Employment status              |                                                                                            |                   |  |  |  |
| Unemployed                     | 227                                                                                        | 22.7              |  |  |  |
| Paid employment                | 210                                                                                        | 21.0              |  |  |  |
| Self-employed                  | 482                                                                                        | 48.2              |  |  |  |
| Others (retired, student)      | 80                                                                                         | 8.1               |  |  |  |
| Average monthly income         |                                                                                            |                   |  |  |  |
| ≤ N 9000                       | 353                                                                                        | 35.3              |  |  |  |
| N 10,000 - 19,000              | 212                                                                                        | 21.2              |  |  |  |
| N 20,000 - 29,000              | 131                                                                                        | 13.1              |  |  |  |
| ≥ N 30,000                     | 303                                                                                        | 30.4              |  |  |  |
| Place of residence             |                                                                                            |                   |  |  |  |
| Urban                          | 583                                                                                        | 58.4              |  |  |  |
| Rural                          | 416                                                                                        | 41.6              |  |  |  |
| Alcohol                        |                                                                                            |                   |  |  |  |
| Consumed                       | 188                                                                                        | 18.9              |  |  |  |
| Never consumed                 | 811                                                                                        | 81.1              |  |  |  |
| Smoke cigarette                |                                                                                            |                   |  |  |  |
| Yes                            | 25                                                                                         | 2.5               |  |  |  |
| No                             | 974                                                                                        | 97.5              |  |  |  |
| Disclosure                     |                                                                                            |                   |  |  |  |
| Yes                            | 913                                                                                        | 91.4              |  |  |  |
| No                             | 86                                                                                         | 8.6               |  |  |  |
| Support from family            |                                                                                            |                   |  |  |  |
| Yes                            | 691                                                                                        | 69.2              |  |  |  |
| No                             | 308                                                                                        | 30.8              |  |  |  |





| Table 2: clinical characteristics of re | espondents on HAART, (   | Cross River State, 2017 |
|-----------------------------------------|--------------------------|-------------------------|
| Variables                               | Frequency (N=999)        | Percentage (100%)       |
| Duration of treatment (months)          |                          |                         |
| <12 months                              | 82                       | 8.2                     |
| 12-24 months                            | 144                      | 14.4                    |
| >24 months                              | 773                      | 77.4                    |
| HAART regimen                           |                          |                         |
| First line                              | 842                      | 84.3                    |
| Second line                             | 157                      | 15.7                    |
| HAART dosing                            |                          |                         |
| Once                                    | 515                      | 51.6                    |
| Twice                                   | 484                      | 48.4                    |
| Number of pills per day                 |                          |                         |
| 1                                       | 497                      | 49.8                    |
| 2                                       | 495                      | 49.5                    |
| ≥3                                      | 7                        | 0.7                     |
| Number of tablets missed/week           |                          |                         |
| 0                                       | 541                      | 54.2                    |
| 1-2                                     | 439                      | 43.9                    |
| ≥3                                      | 19                       | 1.9                     |
| Fluid and food restrictions             |                          |                         |
| No                                      | 995                      | 99.6                    |
| Yes                                     | 4                        | 0.4                     |
| Encountered side effects                |                          |                         |
| No                                      | 956                      | 95.7                    |
| Yes                                     | 43                       | 4.3                     |
| Drug refill                             |                          |                         |
| ≤1 monthly                              | 160                      | 16.0                    |
| 2 monthly                               | 743                      | 74.4                    |
| 3 monthly                               | 96                       | 9.6                     |
| Transport cost to HF                    |                          |                         |
| ≤ ₦ 500 (USD 1.1)                       | 591                      | 59.2                    |
| > ₦ 500 (USD 1.1)                       | 408                      | 40.8                    |
| CD4 count                               |                          |                         |
| < 500                                   | 592                      | 59.3                    |
| ≥ 500                                   | 407                      | 40.7                    |
| HAART: highly active antiretroviral     | therapy; HF: health faci | lity                    |





| Variables                      | respondents' socio-demographics and adherence to HAART  Adherence |                 |           |         |  |
|--------------------------------|-------------------------------------------------------------------|-----------------|-----------|---------|--|
| variables                      | Good adherence                                                    | Poor adherence  | χ2        | P-value |  |
| Age                            | Good dunierence                                                   | 1 oor dunerence | Λ-        | 1 Value |  |
| <43                            | 319(61.9)                                                         | 196(38.1)       | 1.569     | 0.210   |  |
| ≥43                            | 281(58.1)                                                         | 41(41.9)        | 1.505     | 0.210   |  |
| Sex                            | 201(30.1)                                                         | 41(41.5)        |           |         |  |
| Male                           | 182(61.7)                                                         | 113(38.3)       | 0.466     | 0.495   |  |
| Female                         | 418(59.4)                                                         | 286(40.6)       | 0.400     | 0.433   |  |
| Marital status                 | 410(33.4)                                                         | 200(40.0)       |           |         |  |
| Married / cohabiting           | 286(61.4)                                                         | 180(38.6)       | 1.306     | 0.728   |  |
| Separated / divorced           | 39(55.7)                                                          | 31(44.3)        | 1.500     | 0.720   |  |
| Widowed                        | 145(60.7)                                                         | 94(39.3)        |           |         |  |
| Single                         | 130(58.0)                                                         | 94(42.0)        |           |         |  |
| Employment status              | 130(36.0)                                                         | 94(42.0)        |           |         |  |
| Employed Employed              | 47F/61 F)                                                         | 297(38.5)       | 2.054     | 0.081   |  |
| • •                            | 475(61.5)                                                         | ` '             | 3.054     | 0.081   |  |
| Not employed                   | 125(55.1)                                                         | 102(44.9)       |           |         |  |
| Type of settlement /resident   | 200(04.0)                                                         | 247/54.4        | 4 24 4    | 0.020   |  |
| Urban                          | 366(61.0)                                                         | 217(54.4)       | 4.314     | 0.038   |  |
| Rural                          | 234(39.0)                                                         | 182(45.6)       |           |         |  |
| Level of education             | 45/40 5                                                           | 40/54 5         | F 00-     | 0.01-   |  |
| No formal education            | 45(48.4)                                                          | 48(51.6)        | 5.825     | 0.016   |  |
| Formal education               | 555(61.3)                                                         | 351(38.7)       |           |         |  |
| Comorbidities                  |                                                                   |                 |           |         |  |
| No                             | 404(59.0)                                                         | 281(41.0)       | 1.064     | 0.302   |  |
| Yes                            | 196(62.4)                                                         | 118(37.6)       |           |         |  |
| Alcohol                        |                                                                   |                 |           |         |  |
| No                             | 515(63.5)                                                         | 296(35.9)       | 21.282    | <0.001  |  |
| Yes                            | 85(45.2)                                                          | 103(54.8)       |           |         |  |
| Disclosure                     |                                                                   |                 |           |         |  |
| No                             | 54(62.8)                                                          | 32(37.2)        | 0.293     | 0.589   |  |
| Yes                            | 546(59.8)                                                         | 367(40.2)       |           |         |  |
| Family support                 |                                                                   |                 |           |         |  |
| No                             | 201(65.3)                                                         | 107(34.7)       | 5.019     | 0.025   |  |
| Yes                            | 399(57.7)                                                         | 292(42.3)       |           |         |  |
| HAART combination              |                                                                   |                 |           |         |  |
| First line                     | 544(64.6)                                                         | 298(35.4)       | 46.199    | <0.001  |  |
| Second line                    | 56(35.7)                                                          | 101(64.3)       |           |         |  |
| Number of pills per day        |                                                                   |                 |           |         |  |
| ≤2                             | 596(60.1)                                                         | 396(39.9)       | FET 0.000 | 1.000   |  |
| >2                             | 4(57.1)                                                           | 3(42.9)         |           |         |  |
| HAART dosing                   |                                                                   |                 |           |         |  |
| Once daily                     | 269(52.2)                                                         | 246(47.8)       | 27.148    | <0.001  |  |
| Twice daily                    | 331(68.4)                                                         | 153(31.6)       |           |         |  |
| Food and water restriction     |                                                                   |                 |           |         |  |
| No                             | 600(60.3)                                                         | 395(39.7)       | FET 0.000 | 0.025   |  |
| Yes                            | 0(0.0)                                                            | 4(100)          |           |         |  |
| Encountered side effects       |                                                                   |                 |           |         |  |
| No                             | 512(61.5)                                                         | 320(38.5)       | 4.535     | 0.033   |  |
| Yes                            | 88(52.7)                                                          | 79(47.3)        |           |         |  |
| CD4 count                      |                                                                   | - ( /           |           |         |  |
| <500                           | 332(56.1)                                                         | 260(43.9)       | 9.591     | 0.002   |  |
| ≥500                           | 268(65.8)                                                         | 139(34.2)       | 3.331     | 0.002   |  |
| HAART: highly active antiretro |                                                                   |                 | <u> </u>  | 1       |  |





| Table 4: association between treatment profile and adherence to HAART among respondents |            |           |                |         |
|-----------------------------------------------------------------------------------------|------------|-----------|----------------|---------|
| Characteristic                                                                          | Odds ratio | 95% confi | dence interval | p-value |
|                                                                                         |            | Lower     | Upper          |         |
| Median age                                                                              |            |           |                |         |
| < 43                                                                                    | 1          | 0.779     | 1.443          | 0.724   |
| ≥ 43                                                                                    | 1.056      |           |                |         |
| Type of residence                                                                       |            |           |                |         |
| Rural                                                                                   | 1          | 0.674     | 1.306          | 0.714   |
| Urban                                                                                   | 0.938      |           |                |         |
| Educational status                                                                      |            |           |                |         |
| Formal education                                                                        | 1          | 0.801     | 2.150          | 0.280   |
| No formal education                                                                     | 1.313      |           |                |         |
| Drink alcohol                                                                           |            |           |                |         |
| No                                                                                      | 1          | 0.262     | 0.559          | <0.001  |
| Yes                                                                                     | 0.382      |           |                |         |
| HAART combination                                                                       |            |           |                |         |
| Second line                                                                             | 1          | 2.523     | 5.358          | <0.001  |
| First line                                                                              | 3.677      |           |                |         |
| HAART dosing                                                                            |            |           |                |         |
| Once daily                                                                              | 1          | 0.381     | 0.661          | <0.001  |
| Twice daily                                                                             | 0.502      |           |                |         |
| Side effects                                                                            |            |           |                |         |
| No                                                                                      | 1          | 0.547     | 1.129          | 0.192   |
| Yes                                                                                     | 0.786      |           |                |         |
| Food and fluid restriction                                                              |            |           |                |         |
| No                                                                                      | 1          | 0.000     |                | 0.999   |
| Yes                                                                                     | 0.000      |           |                |         |
| CD4 count                                                                               |            |           |                |         |
| < 500                                                                                   | 1          | 0.543     | 0.964          | 0.027   |
| ≥ 500                                                                                   | 0.723      |           |                |         |
| Family support                                                                          |            |           |                |         |
| No                                                                                      | 1          | 0.544     | 0.995          | 0.046   |
| Yes                                                                                     | 0.736      |           |                |         |
| Co-morbidity                                                                            |            |           |                |         |
| No                                                                                      | 1          | 0.659     | 1.330          | 0.714   |
| Yes                                                                                     | 0.936      |           |                |         |
| HAART: highly active antiretrovir                                                       | al therapy | •         | •              |         |








Figure 1: respondents' reasons for missing HAART, Cross River State Nigeria, 2017